Quick Answer
Fulcrum Therapeutics, Inc. reported Net Income of -$74.88 million for fiscal year 2025.
Fulcrum Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$74.88M | -670.0% |
| 2024 | -$9.72M | +90.0% |
| 2023 | -$97.33M | +11.4% |
| 2022 | -$109.87M | -35.9% |
| 2021 | -$80.85M | -14.2% |
| 2020 | -$70.82M | +14.3% |
| 2019 | -$82.68M | -153.7% |
| 2018 | -$32.59M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$19.59M | +9.7% | -13.3% |
| June 30, 2025 | -$17.30M | -131.2% | +2.0% |
| March 31, 2025 | -$17.66M | +34.3% | +18.6% |
| September 30, 2024 | -$21.70M | +9.7% | -139.2% |
| June 30, 2024 | $55.41M | +333.0% | +306.2% |
| March 31, 2024 | -$26.87M | -8.4% | -11.9% |
| September 30, 2023 | -$24.02M | -1.2% | -1.0% |
| June 30, 2023 | -$23.78M | +30.2% | +4.0% |
- Fulcrum Therapeutics, Inc. showed a decrease of -670.0% in Net Income compared to the prior fiscal year.
- Over the 2018–2025 period, Fulcrum Therapeutics, Inc.’s net income has declined by 129.8% (from -$32.59 million to -$74.88 million).
- The most recent figure is from Fulcrum Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: